NEUREVO is developing and will licence first-in-class neuroprotective treatments that effectively protect against multiple neurological disorders. This includes neurodegenerative diseases like ALS or Parkinson's disease and stroke. Our technology is based on the protection and enhancement of mitochondrial function.